Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Outside of the Chair, ExThera Medical Board Composed Entirely of Outside Experts
MARTINEZ, Calif. – -- Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company
Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), vasopressors, and septic shock. He remains an active investigator in the fields of AKI biomarkers, AKI therapeutics and Acute Kidney Disease. He served as an advisor on the Defense Advanced Research Projects Agency (DARPA) $150 million Dialysis-Like Therapy Program that sought to foster emerging, pathogen agnostic blood cleansing countermeasures to respond to the outbreak of sepsis-causing infectious diseases. This program evaluated ExThera’s Seraph technology which is in active use across the United States to treat critically ill COVID-19 patients.
“Dr. Chawla is the preeminent authority on acute kidney injury, sepsis, and the possibilities that extracorporeal filters hold for patients and physicians around the world,” said ExThera Medical Chairman and CEO Robert Ward. “ExThera has already benefited greatly from Dr. Chawla’s expertise. Our efforts to provide a safe and effective device to treat COVID-19 and other emerging diseases can only be elevated by Dr. Chawla’s position on our Board of Directors
Dr. Chawla is the author of over 150 peer-reviewed publications and a recipient of the International Vicenza Award for Critical Care Nephrology; an award that recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide
“Innovation in critical care is indispensable in our fight against the COVID-19 pandemic and the many other challenges posed by emerging infectious diseases,” said Dr. Chawla. “I have been delighted to work with Exthera Medical in developing smart solutions for critically ill patients and look forward to deepening our relationship and continuing to make progress toward saving lives.”
Previously, Dr. Chawla was a Professor of Medicine at the George Washington University (GWU), where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was previously the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center
During his tenure at GWU, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Data from the ATHOS trial was published in the medical journal Critical Care during 2014. In 2015, Dr. Chawla moved from GWU to La Jolla Pharmaceutical Company (LJPC) where he joined as Chief Medical Officer. At LJPC, Dr. Chawla oversaw the development and conduct of the Phase 3 registration ATHOS-3 trial. The data from the ATHOS-3 Trial helped support the FDA approval of GIAPREZA (angiotensin II) which is indicated for the treatment of hypotension due to the treatment of septic or other distributive shock. GIAPREZA was approved on December 21, 2017 and EMA approval in August 2019. Thereafter, Dr. Chawla oversaw the Medical Affairs launch and commercialization of GIAPREZA.